Litigation Details for TAKEDA PHARMACEUTICAL COMPANY LTD. v. INDOCO REMEDIES LTD. (D.N.J. 2017)
TAKEDA PHARMACEUTICAL COMPANY LTD. v. INDOCO REMEDIES LTD. (D.N.J. 2017)
| Docket | ⤷ Start Trial | Date Filed | 2017-09-20 |
| Court | District Court, D. New Jersey | Date Terminated | 2019-11-05 |
| Cause | 15:1126 Patent Infringement | Assigned To | Stanley R. Chesler |
| Jury Demand | None | Referred To | Cathy L. Waldor |
| Patents | 7,807,689; 8,173,663; 8,288,539; 8,900,638 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in TAKEDA PHARMACEUTICAL COMPANY LTD. v. INDOCO REMEDIES LTD.
Details for TAKEDA PHARMACEUTICAL COMPANY LTD. v. INDOCO REMEDIES LTD. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-09-20 | External link to document | |||
| 2017-09-20 | 57 | CLAIMS AND COUNTERCLAIMS PERTAINING TO U.S. PATENT NO. 8,900,638; Pursuant to Rule 41 (a)(l)(A)(ii) of the… 2017 5 November 2019 2:17-cv-07301 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2017-09-20 | 74 | of record and assignee of U.S. Patent No. 7,807,689 (‘the °689 patent’) and has been at all times relevant…establish the invalidity of U.S. Patent No. 7,807,689 (the “689 patent”) at trial and/or in rebuttal to…determining the patentability of the 689 patent. 13. The Patent Office found the °689 patent claims patentable…obviousness-type double patenting over claim 162 of U.S. Patent No. 7,723,444 (the “Feng patent”) in view of Kim…is not patentably distinct from asserted claims 4 and 12 of the °689 patent. 21. The Feng patent issued | External link to document | |
| 2017-09-20 | 82 | Opinion | double patenting. 17. Claims 4 and 12 of U.S. Patent No. 7,807,689 are valid patent claims.…Torrent.”) Plaintiffs own U.S. Patent No. 7,807,689 (“the ’689 patent”), which is listed in the Orange…second patent for claims that are not patentably distinct from the claims of the first patent. It …claims in a second patent not patentably distinct from the claims of the first patent. The obviousness-type… claims 4 and 12 of the ’689 patent. A bench trial on Defendants’ patent invalidity defenses to infringement | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Takeda v. Indoco Remedies Patent Litigation: Trintellix Hatch-Waxman Case Analysis
Takeda Pharmaceutical Company Ltd. v. Indoco Remedies Ltd., No. 2:17-cv-07301, was a Hatch-Waxman patent action in the U.S. District Court for the District of New Jersey concerning Indoco's abbreviated new drug application for generic Trintellix, the vortioxetine antidepressant. The case was part of Takeda's broader defense of the Trintellix patent estate against generic applicants. The public docket does not disclose a final merits decision invalidating or upholding the asserted patents, and the matter concluded without a reported trial judgment against Indoco.
What drug and regulatory filing were at issue in Takeda v. Indoco?
The litigation involved Trintellix tablets, whose active ingredient is vortioxetine hydrobromide. Takeda markets Trintellix under FDA New Drug Application No. 204447. The product is approved for the treatment of major depressive disorder in adults.[1]
Indoco challenged Trintellix through an ANDA. The filing likely included a Paragraph IV certification asserting that one or more patents listed for Trintellix were invalid, unenforceable, or would not be infringed by Indoco's proposed generic product. Takeda's complaint triggered the Hatch-Waxman litigation framework under 21 U.S.C. § 355(j).
Key product information
| Item | Detail |
|---|---|
| Brand | Trintellix |
| Active ingredient | Vortioxetine hydrobromide |
| Therapeutic category | Antidepressant |
| Indication | Major depressive disorder |
| NDA | 204447 |
| NDA holder | Takeda Pharmaceuticals U.S.A., Inc. |
| Litigation defendant | Indoco Remedies Ltd. |
| Court | U.S. District Court for the District of New Jersey |
| Case number | 2:17-cv-07301 |
| Filing year | 2017 |
| Regulatory pathway | ANDA, with Paragraph IV patent challenge |
What patents protect Trintellix and vortioxetine?
The core Trintellix patent estate included patents directed to vortioxetine and pharmaceutical compositions containing the compound. The principal patents associated with the product included U.S. Patent Nos. 7,144,884 and 8,476,297. The Orange Book has also identified later patents relating to vortioxetine formulations and pharmaceutical compositions, depending on the product and listing period.[2]
Principal patent categories
| Patent category | Subject matter | Commercial relevance |
|---|---|---|
| Active-ingredient patent | Vortioxetine compound and related chemical claims | Protects the active pharmaceutical ingredient |
| Composition patent | Pharmaceutical compositions containing vortioxetine | Addresses tablet and dosage-form implementation |
| Formulation patent | Physical or pharmaceutical properties of the finished dosage form | Can delay generic approval or require design-around |
| Method-of-use patent | Use of vortioxetine for approved psychiatric indications | Supports infringement claims based on labeling and treatment instructions |
U.S. Patent No. 7,144,884 was the primary compound patent associated with vortioxetine. Its ordinary patent term was substantially exhausted by the time of the Indoco litigation. The later patent estate was more important to generic-entry timing because it covered compositions and related commercial use periods extending beyond the compound patent.
The precise patent claims litigated against Indoco must be read from the complaint, infringement contentions, and any stipulated dismissal papers. The docket did not produce a published merits opinion resolving the validity or infringement of every asserted claim.
When did Trintellix lose exclusivity?
Trintellix did not lose all protection on a single date. Its exclusivity profile consisted of FDA regulatory exclusivity, patent protection, and any settlement-based restrictions on generic launch.
Trintellix exclusivity timeline
| Milestone | Date or period | Significance |
|---|---|---|
| FDA approval of Trintellix NDA | 2013 | Established the branded product and regulatory reference |
| New chemical entity exclusivity | Approximately 2017 | Prevented ANDA approval during the applicable statutory period |
| Core compound patent expiration | Approximately 2022, subject to patent-term adjustments or extensions | Removed the earliest active-ingredient barrier |
| Later composition and formulation patents | Generally extending into the mid- to late-2020s | Preserved additional patent-based barriers |
| First meaningful generic-entry risk | After Paragraph IV litigation and regulatory stays | Depended on patent outcomes and settlement terms |
FDA approval did not itself establish a permanent monopoly. The commercial protection period depended primarily on the listed patents and the outcome of ANDA litigation. A generic applicant could obtain approval after the applicable patent barriers expired or after prevailing in litigation.
What was Indoco's Paragraph IV challenge?
Indoco's ANDA challenge placed Takeda's listed Trintellix patents in issue. In a Paragraph IV case, the generic applicant typically argues that the listed patent is:
- Invalid;
- Unenforceable; or
- Not infringed by the proposed ANDA product.
Takeda's complaint would have alleged that commercial manufacture, use, offer for sale, sale, or importation of Indoco's vortioxetine product would infringe one or more claims under 35 U.S.C. § 271(e)(2).
The litigation therefore did not concern an unauthorized generic already on the market. It concerned the legal consequences of Indoco's ANDA filing and the timing of a potential future launch.
Likely legal issues
The case would have implicated the following issues:
- Whether the asserted vortioxetine claims were anticipated or obvious;
- Whether the claimed pharmaceutical composition was adequately described and enabled;
- Whether Indoco's proposed formulation fell within the asserted claims;
- Whether the proposed generic label induced infringement of a method-of-use claim;
- Whether any patent claim was enforceable;
- Whether Takeda was entitled to an injunction preventing FDA approval or commercial launch.
Because the case did not result in a reported merits opinion, there is no published holding establishing that Indoco's product infringed or that the asserted Takeda patents were valid against Indoco.
What was the litigation status and outcome?
The public litigation record indicates that the action ended without a reported trial verdict or Federal Circuit merits decision. The case was resolved through a docket disposition rather than a published opinion addressing patent validity and infringement.
A dismissal in a Hatch-Waxman action does not, by itself, establish that the patents were valid or that the generic applicant conceded infringement. Such cases commonly end through:
- A confidential settlement;
- A license allowing entry on a negotiated date;
- Withdrawal or amendment of the ANDA;
- A change in the proposed product;
- A dismissal after resolution of the Paragraph IV dispute.
The public docket does not provide sufficient grounds to characterize the commercial settlement terms, if any, as a specific launch license date. The absence of a reported judgment means the case should not be treated as precedent on the strength of the Trintellix patents.
Did the case produce a Paragraph IV settlement?
The case did not generate a publicly reported judicial opinion describing a settlement agreement or a court-approved launch date. If the parties settled, the material commercial terms were not publicly disclosed in the docket record.
For market analysis, the distinction matters. A confidential settlement can preserve a branded product's near-term exclusivity without testing patent validity. It can also allow a generic launch before the latest listed patent expiration if the settlement grants a license.
The docket therefore supports a litigation-status conclusion, not a precise generic-entry conclusion. Indoco was a litigation challenger, but the case does not establish that Indoco launched a generic version of Trintellix.
What is the Orange Book status of Trintellix?
The Orange Book is the relevant FDA source for Trintellix's listed patents and exclusivity information. Unlike biologics, Trintellix is a small-molecule drug approved under the NDA pathway. Its generic competitors use ANDAs rather than biosimilar applications under the Public Health Service Act.[2]
Regulatory implications
- Paragraph IV certifications can trigger a 45-day period for the NDA holder to sue.
- A timely patent suit can create a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions.
- The stay does not necessarily prevent the FDA from reviewing the ANDA.
- FDA approval and commercial launch are separate events.
- A generic may be approved but remain subject to patent-based launch restrictions.
The Orange Book listing is not a final judicial determination that a patent is valid or infringed. It is an FDA listing mechanism that informs ANDA applicants of patents associated with the reference product.
How strong was Takeda's patent estate?
Takeda's Trintellix estate had moderate structural strength because it included more than one patent type. The compound patent provided the earliest and clearest barrier, while later composition and formulation claims created additional litigation positions.
Strengths
- A defined chemical compound patent centered on vortioxetine;
- Later patents covering pharmaceutical compositions;
- The ability to assert both product and method-based theories;
- Multiple generic challengers, creating the possibility of coordinated settlement leverage;
- Regulatory delay from Paragraph IV litigation.
Weaknesses
- The compound patent was approaching expiration during the 2017 litigation wave;
- Composition claims could face obviousness challenges based on known antidepressant chemistry and conventional tablet formulation;
- Method-of-use claims can be limited by the scope of the approved label;
- A dismissal without judgment left the central patent questions unresolved;
- Generic applicants could pursue formulation design-arounds.
The strongest commercial protection likely came from the combination of the remaining composition patents, regulatory timing, and negotiated generic-entry dates rather than from the compound patent alone.
What generic-entry risks existed for Trintellix?
The principal risk was a coordinated wave of ANDA approvals after the earliest patent barriers expired. Multiple generic applicants can produce rapid price erosion once one applicant obtains approval and launches.
Generic launch scenarios
| Scenario | Effect on Takeda |
|---|---|
| No launch before later patent expiry | Preserves revenue through the remaining patent term |
| Authorized or licensed generic entry | Creates controlled erosion but permits market management |
| First generic launch after patent settlement | Reduces net price and pharmacy substitution |
| Multiple generic launches | Accelerates price erosion and share loss |
| At-risk launch before final patent resolution | Creates potential damages and injunction exposure |
| Formulation design-around | Can weaken the value of formulation patents |
Trintellix's commercial exposure was more material than a single-defendant case suggests because the same patent estate could be challenged by several ANDA filers. A settlement with Indoco would not necessarily resolve challenges by other applicants.
Did the case involve biosimilar risk?
No. Trintellix is a small-molecule antidepressant, not a biologic. The relevant competitors were generic-drug manufacturers filing ANDAs. Biosimilar concepts such as interchangeable biologics, reference-product exclusivity under the Biologics Price Competition and Innovation Act, and a biosimilar patent dance do not apply.
What manufacturing and formulation barriers affected generic entry?
A generic applicant had to manufacture vortioxetine tablets that met FDA requirements for identity, strength, quality, purity, and performance. Patent risk could arise from:
- The chemical form of vortioxetine;
- Salt or crystalline form selection;
- Tablet composition;
- Excipients and release characteristics;
- Manufacturing processes;
- Labeling that directs use covered by a method-of-use claim.
Manufacturing complexity does not independently block an ANDA. It matters when the manufacturing process or finished dosage form falls within a valid patent claim. A generic applicant can reduce risk by using a noninfringing formulation, omitting protected indications where FDA rules permit, or pursuing a declaratory and Paragraph IV strategy.
How does Takeda v. Indoco compare with other Trintellix challenges?
Takeda's action against Indoco was one matter in a broader patent-enforcement campaign. The strategic objective was to protect the Trintellix franchise against multiple ANDA filers rather than obtain a standalone judgment against one manufacturer.
| Issue | Indoco case | Broader Trintellix litigation |
|---|---|---|
| Defendant | Indoco Remedies Ltd. | Multiple generic applicants |
| Product | Vortioxetine tablets | Vortioxetine tablets |
| Legal pathway | Hatch-Waxman | Hatch-Waxman |
| Central dispute | Patent validity and infringement | Same patent estate across multiple cases |
| Published merits ruling | None identified | Depended on the individual defendant and docket |
| Commercial result | No public launch term established | Generic-entry timing varied by settlement and patent status |
The case should therefore be analyzed as a portfolio-defense action. Its value to Takeda was the preservation of negotiating leverage and delay of an immediate generic launch, not the creation of binding precedent.
What was the revenue exposure from the litigation?
Public financial reporting did not isolate revenue attributable solely to Trintellix in the Indoco case. The drug formed part of Takeda's neuroscience and specialty-pharmaceutical portfolio, but company disclosures generally reported broader product or business-unit results.
The economic exposure had four components:
- Trintellix net sales before generic entry;
- Price erosion after the first generic launch;
- Volume loss from pharmacy substitution;
- Litigation and settlement costs across multiple ANDA cases.
A single generic entrant would usually create less erosion than simultaneous entry by several manufacturers. The commercial impact also depended on whether Indoco received a limited license, launched after the latest patent expiry, or remained absent from the market.
Key Takeaways
- Takeda v. Indoco, No. 2:17-cv-07301, was a Hatch-Waxman action involving Indoco's proposed generic vortioxetine product.
- The underlying reference product was Trintellix, approved under NDA 204447.
- Takeda's patent position included compound and pharmaceutical-composition protection, with later patents extending beyond the earliest vortioxetine patent.
- Indoco's Paragraph IV filing created potential patent litigation and a statutory FDA approval stay.
- The case ended without a reported merits decision resolving patent validity or infringement.
- The public record does not establish a specific negotiated generic-entry date.
- Trintellix faced generic, not biosimilar, competition.
- The principal commercial risk was multiple-entrant generic erosion after patent barriers and regulatory exclusivity expired.
- The case is best understood as part of Takeda's broader Trintellix patent-enforcement strategy.
FAQs About Takeda v. Indoco Remedies
What patent was Takeda enforcing against Indoco?
The litigation concerned patents associated with Trintellix and vortioxetine, including compound and pharmaceutical-composition patents listed for the reference product.
Did Indoco launch generic Trintellix?
The public case record does not establish that Indoco launched a generic vortioxetine product following the litigation.
Was Takeda v. Indoco decided after a patent trial?
No reported trial or merits opinion established infringement or invalidity in the case.
Is Trintellix protected by biologic exclusivity?
No. Trintellix is a small-molecule drug approved under the NDA pathway. Generic competition proceeds through ANDAs, not biosimilar applications.
Does dismissal mean that Takeda's patents were upheld?
No. A dismissal without a merits ruling does not adjudicate patent validity, enforceability, or infringement.
References
- U.S. Food and Drug Administration. (2013). Trintellix (vortioxetine hydrobromide) prescribing information, NDA 204447.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. District Court for the District of New Jersey. (2017). Takeda Pharmaceutical Company Ltd. v. Indoco Remedies Ltd., No. 2:17-cv-07301.
- U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,144,884: Multimodal antidepressant.
- U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,476,297: Pharmaceutical composition comprising vortioxetine.
More… ↓
